Analyst Price Targets — PRVA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 8, 2026 1:15 pm | — | Evercore ISI | $26.00 | $22.71 | TheFly | Privia Health price target lowered to $26 from $30 at Evercore ISI |
| February 26, 2026 8:26 pm | Jack Slevin | Jefferies | $32.00 | $24.91 | StreetInsider | Privia Health Group Inc (PRVA) PT Raised to $32 at Jefferies |
| February 26, 2026 7:34 pm | Jessica Tassan | Piper Sandler | $36.00 | $24.91 | StreetInsider | Privia Health Group Inc (PRVA) PT Raised to $36 at Piper Sandler |
| January 9, 2026 12:19 pm | — | RBC Capital | $31.00 | $23.15 | TheFly | Privia Health resumed with an Outperform at RBC Capital |
| January 6, 2026 9:57 am | — | Wolfe Research | $31.00 | $24.14 | StreetInsider | Privia Health Group (PRVA) Reiterated at Market Outperform by Citizens |
| November 12, 2025 12:02 pm | — | Canaccord Genuity | $34.00 | $24.32 | TheFly | Privia Health price target raised to $34 from $32 at Canaccord |
| October 9, 2025 9:49 am | — | Barclays | $22.00 | $24.53 | TheFly | Privia Health price target raised to $22 from $21 at Barclays |
| August 29, 2025 8:41 am | — | JMP Securities | $30.00 | $21.81 | TheFly | Privia Health price target raised to $30 from $29 at Citizens JMP |
| April 15, 2025 9:40 am | Michael Ha | Robert W. Baird | $26.00 | $24.10 | TheFly | Privia Health price target raised to $26 from $24 at Baird |
| February 28, 2025 12:21 pm | — | JMP Securities | $29.00 | $24.97 | TheFly | Privia Health price target raised to $29 from $26 at Citizens JMP |
Latest News for PRVA
ARLINGTON, Va., April 08, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its first quarter ended March 31, 2026 before market open on Thursday, May 7, 2026.
JPMorgan Chase and Co. increased its holdings in Privia Health Group, Inc. (NASDAQ: PRVA) by 26.2% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 148,709 shares of the company's stock after acquiring an additional 30,845 shares during
ARLINGTON, Va., March 24, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced that its network of affiliated medical groups, collectively Privia Medical Group, has been named a recipient of the 2026 MAP (Measure, Apply, Perform) Award for High Performance in Revenue Cycle, sponsored by the Healthcare Financial Management Association (HFMA).
Privia Health's CFO sold 13,018 direct shares for approximately $283,000 over two days, at an average price of $21.71 per share. The sale represented 5.24% of the CFO's total direct holdings as of the transaction dates.
The average of price targets set by Wall Street analysts indicates a potential upside of 43.4% in Privia Health (PRVA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PRVA.
U.S. House Trading
No House trades found for PRVA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.